Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ALDOA drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild-Type) | ALDOA Full-Length Recombinant Protein, High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. | View ALDOA Products |
| Antigen (Mutant) | ALDOA Active Site Mutants (Lys146Arg, Cys338Ala) for mechanistic studies and drug resistance screening. | View ALDOA Products |
| Gene Delivery | ALDOA Promise-ORF / Lentivirus with CMV promoter for stable cell line construction. | View ALDOA Products |
| Benchmark Antibody | Anti-ALDOA (Biosimilar Sequence) – recombinant positive control antibody. | View ALDOA Products |
| Detection Antibody | Anti-ALDOA Monoclonal Antibody – WB/IHC validated, recombinant sequence. | View ALDOA Products |
| Validator | ALDOA siRNA Set (3 unique targets) for knockdown verification in metabolic assays. | View ALDOA Products |
| Related Target A | HIF1A – Upstream master regulator driving ALDOA overexpression in the hypoxic tumor microenvironment. | View HIF1A Products |
| Related Target B | ALDOB – Liver-specific isoform for selectivity profiling and safety counter-screening. | View ALDOB Products |
| Related Target C | PKM2 – Warburg effect synergistic target (pyruvate kinase M2). | View PKM2 Products |
| Related Target D | GAPDH – Glycolytic pathway partner for combination studies. | View GAPDH Products |
Critical Assay Challenges and TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (ALDOA vs ALDOB/C) | Human ALDOA/B/C Ortholog Panel (>95% purity, Mass Spec Verified) for cross-reactivity elimination. |
| Preservation of Allosteric Sites | Native folding preserved via HEK293 expression system; structural integrity maintained for small molecule screening. |
| Lack of Validated Controls | High-purity recombinant positive control antibodies available. |
| False Positives in Phenotypic Screens | Sequence-verified siRNA included for precise specificity checks and target validation. |
| Enzymatic Activity Preservation | Native folding verified by Circular Dichroism; retains fructose-1,6-bisphosphate cleavage activity. |
| Drug Resistance Mutation Analysis | Active site mutants (Lys146, Cys338) available for mechanistic escape studies. |
| Cellular Metabolism Validation | High-titer Lentivirus (>1×10^8 TU/ml) for stable overexpression in cancer cell lines. |
Live ALDOA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Cancer Metabolism Research
- ➤ Latest Resistance & Isoform Switching Studies
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The therapeutic targeting of ALDOA represents a paradigm shift in metabolic oncology, exploiting the Warburg effect in solid tumors. Current R&D focuses on small molecule active site inhibitors and allosteric modulators that can distinguish between ALDOA (muscle/cancer-associated) and ALDOB (liver-specific) isoforms. As first-generation metabolic inhibitors enter preclinical safety evaluations, the field is pivoting toward combination strategies with immune checkpoint inhibitors and PI3K pathway modulators, as well as synthetic lethality paradigms that pair ALDOA inhibition with standard-of-care chemotherapeutics or immunotherapies to overcome metabolic-driven drug resistance. The next wave includes targeted degraders (PROTACs) and siRNA approaches for modulating ALDOA expression in hypoxic solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Active Site) | Academic Consortia, Emerging Metabolic Biotechs | Solid Tumors (Lung, Breast, Hepatocellular) | Isoform Selectivity Panel (ALDOA vs ALDOB) – Need highly pure ortholog proteins |
| Small Molecule (Allosteric) | Preclinical Biotech | NSCLC, Pancreatic Cancer | Selectivity Assay (Need High-Purity Homolog Panel: ALDOA/B/C) |
| PROTAC Degrader | Academic / Early Pharma, Targeted Protein Degradation Startups | Hypoxic Solid Tumors, Metastatic Cancers | Degradation Assay (Need specific antibodies and stable cell lines); Protein-Protein Interaction Assays |
| siRNA / RNAi | Emerging Biopharma | Liver Metastases | Knockdown Validation (Need Sequence-Verified siRNA sets) |
| Combination Therapy | Global Pharma | Chemo-Refractory Tumors | Mechanism Assays (Need pure recombinant proteins for interaction mapping) |
| Allosteric Modulator | Structural Biology Groups | Diabetes, Metabolic Syndrome | Thermal Shift Assays – Need conformationally stable WT and mutant proteins |
| Metabolic Flux Analysis | Systems Biology Platforms | Drug Resistance Studies | Stable Cell Line Construction – Need Lentivirus for consistent overexpression |
Key Mutations and Disease Association
ALDOA mutations are associated with Glycogen Storage Disease XII (GSD12), characterized by thermolabile enzyme variants. Key dbSNP variants include:
- rs11553107 (UniProt VAR_048219): A missense variant of uncertain significance.
- rs121909533 (UniProt VAR_000550): The GSD12-associated thermolabile mutation.
- rs11553108 (UniProt VAR_048220): Another missense variant.
These mutations are important for understanding disease mechanisms and drug resistance. TarMart offers recombinant mutant proteins (e.g., Lys146Arg, Cys338Ala) for mechanistic studies.